Vivani Medical Inc (VANI) does not present a strong buying opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are bearish, options data shows minimal activity, and there are no recent positive news or catalysts. Analyst ratings are positive but with a lowered price target, and the stock's trend suggests potential short-term declines. Given these factors, holding off on buying is recommended.
The technical indicators for VANI are bearish. The MACD histogram is negative and contracting, RSI is neutral at 44.055, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.107, and resistance is at 1.229. The stock's trend suggests a 60% chance of declining by -0.64% in the next day, -2.55% in the next week, and -11.41% in the next month.

Analyst Yi Chen maintains a Buy rating, citing potential efficacy of NPM-139 comparable to Wegovy with less frequent administration.
Additionally, the stock trend analysis suggests potential short-term declines.
No financial data available for analysis.
H.C. Wainwright analyst Yi Chen maintains a Buy rating but has lowered the price target to $3.50 from $4 due to an increased share count.